See more : Jones Soda Co. (JSDA) Income Statement Analysis – Financial Results
Complete financial analysis of Intech Biopharm Corporation (6461.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intech Biopharm Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Banco BMG S.A. (BMGB4.SA) Income Statement Analysis – Financial Results
- Rare Earth Magnesium Technology Group Holdings Limited (0601.HK) Income Statement Analysis – Financial Results
- Epuja Spiritech Ltd. (SAGARPROD.BO) Income Statement Analysis – Financial Results
- Greenfern Industries Limited (GFI.NZ) Income Statement Analysis – Financial Results
- V. B. Industries Limited (VBIND.BO) Income Statement Analysis – Financial Results
Intech Biopharm Corporation (6461.TWO)
About Intech Biopharm Corporation
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 25.85M | 23.65M | 38.90M | 21.11M | 0.00 |
| Cost of Revenue | 189.84M | 170.91M | 158.27M | 160.00M | 0.00 |
| Gross Profit | -164.00M | -147.26M | -119.37M | -138.89M | 0.00 |
| Gross Profit Ratio | -634.48% | -622.75% | -306.87% | -658.07% | 0.00% |
| Research & Development | 104.49M | 118.68M | 126.63M | 62.32M | 0.00 |
| General & Administrative | 44.12M | 45.23M | 41.89M | 33.06M | 0.00 |
| Selling & Marketing | 7.86M | 6.92M | 6.09M | 6.29M | 0.00 |
| SG&A | 51.99M | 52.14M | 47.98M | 39.35M | 0.00 |
| Other Expenses | 0.00 | 11.31M | 10.92M | 6.28M | 0.00 |
| Operating Expenses | -164.00M | 170.82M | 174.61M | 101.67M | 0.00 |
| Cost & Expenses | 346.32M | 341.73M | 332.88M | 261.67M | 0.00 |
| Interest Income | 4.42M | 1.93M | 848.00K | 723.00K | 329.00K |
| Interest Expense | 33.59M | 23.04M | 19.54M | 16.81M | 19.31M |
| Depreciation & Amortization | 84.81M | 85.36M | 85.30M | 84.95M | 0.00 |
| EBITDA | -219.59M | -219.48M | -197.40M | -148.61M | -217.64M |
| EBITDA Ratio | -849.56% | -928.16% | -506.23% | -704.12% | 0.00% |
| Operating Income | -320.47M | -304.84M | -282.22M | -233.56M | 0.00 |
| Operating Income Ratio | -1,239.87% | -1,289.11% | -725.51% | -1,106.60% | 0.00% |
| Total Other Income/Expenses | -17.52M | -9.80M | -19.54M | -9.81M | -11.72M |
| Income Before Tax | -337.99M | -327.88M | -301.76M | -250.37M | 0.00 |
| Income Before Tax Ratio | -1,307.64% | -1,386.55% | -775.74% | -1,186.25% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -337.99M | -327.88M | -301.76M | -250.37M | 0.00 |
| Net Income Ratio | -1,307.64% | -1,386.55% | -775.74% | -1,186.25% | 0.00% |
| EPS | -2.81 | -2.82 | -2.89 | -2.42 | 0.00 |
| EPS Diluted | -2.81 | -2.82 | -2.89 | -2.42 | 0.00 |
| Weighted Avg Shares Out | 120.46M | 116.13M | 104.40M | 103.51M | 103.51M |
| Weighted Avg Shares Out (Dil) | 120.46M | 116.13M | 104.40M | 103.51M | 103.51M |
Source: https://incomestatements.info
Category: Stock Reports